ClinicalTrials.gg
RecruitingNCT05157126GO-TibiaUpdated Sep 10, 2026

Gentamicin Open Tibia Study

A Phase 4 interventional study of Gentamicin and normal Saline in Fracture Open Tibia, sponsored by University of California, San Francisco. Recruiting at 1 site in Tanzania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
890
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Local application of antibiotics directly to the traumatic wound is a promising treatment for the prevention of infection after open tibia fractures, which are a significant source of disease burden globally, particularly in low-income countries. This study aims to measure the effect of locally applied gentamicin on risk of infection for open tibial fractures in Tanzania. If proven effective, local gentamicin would be a highly cost-effective strategy to reduce complications and disability from open tibial fractures that could impact care in both high- and low-income countries.

Read the detailed description

Tibial shaft (shinbone) fractures are the most common major fracture of the lower leg and are frequently associated with a break in the skin known as an open fracture. Because the bone is exposed by the open wound, open tibial fractures are often complicated by infection and failure of bone healing, which can lead to long-lasting disability and in some cases amputation. Intravenous antibiotics administered early after injury are a well-established measure to prevent fracture-related infection (FRI), but their effectiveness is limited by poor blood flow at the fracture site and inability to achieve high local concentrations with systemic administration. Gentamicin applied locally within the open fracture wound is a promising adjunctive measure to reduce the risk of FRI after these injuries, but there are no high-quality clinical trials evaluating its use.

This will be the first randomized trial evaluating locally administered gentamicin to reduce infection in a fracture population. If efficacious, local gentamicin is likely to be a highly cost-effective preventive strategy for FRI and may ultimately be cost saving. Although these findings will originate from a low-income country, results may be generalizable to populations in both high and low-income countries and could therefore significantly reduce the global burden of open fractures.

02

Conditions studied

  • Fracture Open Tibia

Browse trials for

03

In context

Fractures, Open

53 studies on the registry are indexed under Fractures, Open; 14 are open to participants now.

This study's planned enrollment of 890 is above the median of 90 across 40 interventional studies indexed under Fractures, Open.

Browse Fractures, Open studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>18 years old
  • Open tibial shaft fracture meeting the following criteria:

    1. Orthopaed Trauma Association (OTA) Type 42
    2. Primarily closable wound
    3. Gustilo-Anderson (GA) Type I, II, or IIIA

Exclusion criteria

Exclusion Criteria:

  • Time from injury to presentation > 48 hours
  • Time from injury to surgery > 7 days
  • Aminoglycoside allergy
  • GA IIIB or IIIC open fractures
  • Bilateral open tibial fractures
  • Severe brain (GCS\<12) or spinal cord injury
  • Severe vascular injury
  • Severe burns (>10% Total Body Surface Area (TBSA) or >5% TBSA with full thickness or circumferential injury)
  • Pathologic fracture
  • History of active limb infection, ipsilaterally
  • Unlikely to complete follow-up
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
890 participants (estimated)

Study arms

  • Experimental
    Gentamicin

    The intervention consists of 80mg of liquid gentamicin diluted in 5 mL normal saline (16mg/mL). The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.

    Drug: Gentamicin

  • Placebo comparator
    Saline

    The control consists of 5 mL normal saline injected immediately after wound closure at the open fracture site. The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.

    Drug: normal Saline

Interventions

  • Liquid gentamicin administered at the open fracture site

  • Drugnormal Saline

    Normal saline administered at the open fracture site

06

What researchers measure

Primary outcomes

  1. Occurrence of fracture-related infection (FRI)

    Fracture-related infection is a consensus definition of infection after fracture treatment. It is diagnosed by an orthopaedic surgeon based on any of the following four diagnostic criteria: (1) fistula, sinus or wound breakdown; (2) purulent drainage from the wound or presence of pus during surgery; (3) phenotypically indistinguishable pathogens identified by culture from at least two separate deep tissue/implant specimens; or (4) presence of microorganisms in deep tissue taken during an operative intervention, as seen on histopathological examination. FRI diagnosis is likely to peak between 6 weeks and 6 months after surgery and has a non-normal time-to-event distribution, with incident cases rarely presenting later than 12 months after surgery. All events will be confirmed by an independent adjudication committee comprised of three masked, non-treating orthopaedic trauma surgeons.

    Time frame: 12 months

Secondary outcomes

  1. Occurrence of nonunion

    Binary outcome based on the following criteria: 1. Any unplanned reoperation for promotion of bone healing; OR 2. Modified Radiographic Union Scale for Tibia Fractures (mRUST) ≤10 at 12 months follow-up AND either: Function IndeX for Trauma (FIX-IT) score ≤11 at 12 month follow-up, OR recommendation by treating surgeon for nonunion repair surgery

    Time frame: 12 months

  2. Occurrence of unplanned fracture-related reoperation

    Occurrence of unplanned fracture-related reoperation, a binary variable, for infection, wound healing, or fracture union, excluding removal of implants for prominence/irritation. This may include but is not limited to: 1. Irrigation and debridement of surgical incisions or open fracture wounds due to infections or wound healing problems; 2. Revision wound closure for dehiscence; 3. Soft tissue coverage procedure for infected or necrotic wound; 4. Fracture delayed union or nonunion surgery (such as bone grafting or implant exchange); 5. Reoperation for hardware or prosthesis failure due to infection or bone-healing problems; 6. Amputation for infection, wound or fracture healing problem.

    Time frame: 12 months

  3. Health-related quality-of-life (HRQOL) as measured by EQ-5D-3L (Swahili version)

    The EQ-5D is a survey instrument that assesses multiple domains of quality-of-life, including mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

    Time frame: 12 months

  4. Fracture healing by modified Radiographic Union Scale for Tibial fractures (mRUST score)

    The mRUST score is based on evaluation plain radiographs of the fracture site. Each cortex is scored from 1-4 based on the degree of healing and summed resulting in an ordinal scale ranging from 4 to 16, with higher score indicating greater fracture healing.

    Time frame: 12 months

  5. Clinical fracture healing by Function IndeX for Trauma (FIX-IT)

    The FIX-IT score is an ordinal scale from 0-12 that encompasses two domains: ability to weight-bear and pain at fracture site, each scored from 0-6. Higher score indicates more clinical healing.

    Time frame: 12 months

  6. Occurence of FRI Suggestive Criteria

    Suggestive criteria are signs/symptoms of infection that do not meet criteria for definitive fracture-related infection (FRI). These include clinical signs (wound redness, fever) and radiographic signs (sequestrum), elevated serum inflammatory markers, and new onset or increased non-purulent wound drainage.

    Time frame: 12 months

Other outcomes

  1. Adverse events

    All serious and non-serious adverse events will be reported as counts for each treatment group

    Time frame: 12 months

  2. Fold-change in creatinine level

    Creatinine is a laboratory value used to assess kidney function. Creatinine levels will be measured preoperatively and 2-days postoperatively for all study participants.

    Time frame: 2 days

07

Study locations

1 of 1 sites recruiting
  • Muhimbili Orthopaedic Institute
    Dar es Salaam, Tanzania
    Recruiting
    • Billy T Haonga, MD · Contact255-022-2151298
    • Billy T Haonga, MD · Principal investigator
08

References and documents

Publications

  • Haonga BT, O'Marr JM, Ngunyale P, Ngahyoma J, Kessey J, Sasillo I, Rodarte P, Belaye T, Berhaneselase E, Eliezer E, Porco TC, Morshed S, Shearer DW. GO-Tibia: a masked, randomized control trial evaluating gentamicin versus saline in open tibia fractures. Trials. 2023 Jun 15;24(1):406. doi: 10.1186/s13063-023-07410-0. PubMed 37322521 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05157126
Collaborators
Muhimbili Orthopaedic Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Orthopedic Research and Education Foundation
Responsible party
Sponsor
First posted
Dec 14, 2021
Start date
Sep 1, 2022
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Sep 10, 2026

Study contacts

David W Shearer, MD, MPH
Contact
david.shearer@ucsf.edu
628-206-8812
Tigist Belaye, MPA
Contact
tigist.belaye@ucsf.edu
628-206-8812
David W Shearer, MD, MPH
principal investigator · University of California, San Francisco
Billy T Haonga, MD
principal investigator · Muhimbili Orthopaedic Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gentamicins

Start the discussion